DATA GRAPHICS | Data Byte
Immunology takeouts led by IgA nephropathy, IBD
Seven of 11 $1B+ immunology acquisitions focused on two diseases
March 27, 2025 10:45 PM UTC
Biopharmas cited immunology as the motivation for 11 M&A deals with upfront valuations over $1 billion in 2022-24. Of those, four of the acquired companies had lead products in the rare autoimmune kidney disease IgA nephropathy, while three were testing treatments for inflammatory bowel diseases.
The class includes the second-largest acquisition of the past three years, Amgen Inc. (NASDAQ:AMGN) paying $27.8 billion for Horizon Therapeutics plc. The deal gave Amgen three marketed drugs for rare inflammatory conditions: Tepezza teprotumumab for thyroid eye disease, Krystexxa pegloticase for gout, and Uplizna inebilizumab to treat neuromyelitis optica spectrum disorder (NMOSD)...